Abstract 465P
Background
Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric central nervous system tumors, and currently, there are no curative treatment options available. With the increasing application of molecular diagnostics, more and more DIPG patients are recommended to undergo surgery; however, its correlation with dissemination needs to be better understood. Hence, we conducted this cohort to analyze the predictors of subsequent metastasis in pediatric DIPGs.
Methods
The final analysis included 142 pediatric (age ≤ 12) DIPG patients treated at Sanjiu Brain Hospital between January 2017 and September 2023. The data were retrospectively collected following the initial diagnosis. Patients were followed up for 6 months. The primary endpoint was the occurrence of subsequent metastasis. Univariable and multivariable logistic regression analyses were utilized to identify statistically significant predictors of subsequent dissemination. All statistical assessments were two-tailed, and only P < 0.05 was deemed to be statistically significant.
Results
Among 142 patients, 14 (9.9%) developed metastasis within the follow-up time. There were 77 (54.2%) males and 65 (45.8%) females. The median age was 7 years (ranging 1 - 12 years). The overall cohort demonstrated that surgery was the only predictor of dissemination both in univariable (OR 4.567, 95%CI 1.351 – 20.901, P = 0.024) and multivariable (OR 5.501, 95%CI 1.560 – 26.105, P = 0.014) analyses. However, subgroup analysis involving patients who received surgical intervention showed that biopsy was not superior nor inferior to resection in terms of relative risk for subsequent dissemination (16.7% vs. 15.8%).
Conclusions
Surgical intervention increases the relative risk of dissemination occurrence to four times more than those who did not receive surgery. Surgical intervention is crucial given the potential of molecular analysis leading to improved therapeutic options. Nonetheless, patients should be informed about the risks associated with surgery, including subsequent metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16
458P - Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Presenter: Diya Jayram
Session: Poster session 16
459P - Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US
Presenter: Jennifer Connelly
Session: Poster session 16
460P - Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Presenter: Zelei Dai
Session: Poster session 16
461P - Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Presenter: Marta Padovan
Session: Poster session 16
462P - Regorafenib for relapsed glioblastoma: Retrospective real-world analysis of a single Institution experience
Presenter: Giulia Rovesti
Session: Poster session 16
463P - Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
Presenter: Madison Sherman
Session: Poster session 16
466P - Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Presenter: Olga Regentova
Session: Poster session 16
Resources:
Abstract
467P - Temozolomide potentially postpones the development of subsequent metastases in pediatric diffuse intrinsic pontine glioma (DIPG) patients
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract